Skip to main content

For informational and research purposes only.

Medical DisclaimerTerms of Use

UC-II Undenatured Type II Collagen: The Definitive Guide

UC-II is a branded undenatured type II collagen ingredient studied in milligrams. It is not interchangeable with gram-dose hydrolyzed collagen peptides.

Form, active amount, population and outcome stay connected.
Published by DoserlyUpdated Next scheduled review: January 20276 min readHow this guide was made
In this guide

What is UC-II Undenatured Type II Collagen?

UC-II is a branded undenatured type II collagen ingredient studied in milligrams. It is not interchangeable with gram-dose hydrolyzed collagen peptides. No RDA, AI, UL or established general treatment dose exists for UC-II. The repeated 40 mg/day schedule belongs to specific branded-product trials.

Typical UC-II Undenatured Type II Collagen Protocols

Research schedules and references only; these are not prescriptions.
Source and populationForm and amount each timeFrequencyTotal exposureDuration or boundary
Lugo 2016 · 191 adults with knee OABranded undenatured type II collagen 40 mgOnce daily40 mg/day180 days; WOMAC versus placebo and glucosamine/chondroitin
Crowley 2009 · knee OAUC-II 40 mgOnce daily40 mg/day90 days; active comparison
Lugo 2013 · 55 healthy adults with activity discomfortUC-II 40 mgOnce daily40 mg/day120 days; knee extension and time to discomfort

These rows reproduce sources. Do not average them into one universal regimen.

Source, active amount and outcome stay attached. Sources: Reference source · Human study.

Which forms and label details matter?

Record undenatured versus hydrolyzed collagen, collagen type, chicken-cartilage source, proprietary identity, total ingredient mass and any declared active type II collagen. Heat and processing can change native structure.

How should it be stored?

Follow the label, close the container and protect it from heat, light and moisture.

Product mass and active amounts are not interchangeable. Sources: Reference source.

What is it commonly used for?

UC-II is used for knee-osteoarthritis symptoms and activity-related knee discomfort. Trials measured symptoms and range of motion, not cartilage regrowth or fracture prevention.

What does human research show?

A multicentre trial randomized 191 adults with knee osteoarthritis to UC-II 40 mg/day, glucosamine hydrochloride plus chondroitin sulfate, or placebo for 180 days. UC-II improved total WOMAC versus placebo and the active combination, but the result remains tied to the proprietary ingredient and sponsor-linked evidence base. [1] A 55-person trial in otherwise healthy adults with exercise-related knee discomfort used 40 mg once daily for 120 days and reported selected range-of-motion and discomfort-timing improvements. [3] A later 24-week multicentre study also assessed activity-related discomfort; these symptom and flexibility outcomes do not establish cartilage regeneration. [4] The earlier active-comparator study likewise remains product-specific. [2]

Simplified conceptual trabecular-bone anatomy.
Simplified bone context; it is not microscopy and does not demonstrate cartilage repair, bone gain or a supplement effect.

How might it act?

Biological plausibility does not establish a clinical outcome. The guide therefore keeps preparation, population and endpoint attached to each result.

How does it compare with related products?

ProductIdentity to preserveEvidence boundary
GlucosamineSulfate or hydrochloride; active amountForm-specific osteoarthritis evidence
ChondroitinChondroitin sulfate and product qualitySymptom and structure outcomes differ
UC-II collagenUndenatured type II collagenMilligram-dose proprietary trials
CollagenHydrolyzed peptides, source and gramsPeptide trials do not transfer to UC-II

What are the risks and interactions?

GI symptoms and headache can occur. Chicken-cartilage source matters for allergy and dietary restrictions. Review pregnancy, breastfeeding, autoimmune disease, immunosuppressive therapy and concurrent osteoarthritis treatment; do not delay assessment of a hot, swollen, locked or injured joint.

Which medicines require review?

Have the product reviewed with medicines, before surgery, and during pregnancy or breastfeeding. No universal separation interval is established.

Regulatory status: In the United States, supplements generally lack premarket efficacy approval. In Canada, verify the finished product’s NPN or DIN-HM and licensed conditions. [5], [6]

What should be monitored?

Record product, lot, form, amount per administration, frequency, daily total, co-ingredients, meals, symptoms, medicines, chosen outcome and review date.

What happens when it is stopped?

No ingredient-specific withdrawal syndrome is established. Record the stop date, symptoms and chosen outcome; seek care for a persistent serious symptom.

Seek prompt care for a serious allergic reaction, unusual bleeding, persistent palpitations, chest pain or another severe symptom.

What do public communities report?

Public reports can suggest questions to track, but they do not verify the product, dose or causality. This update did not newly quantify a community sample.

Common questions about UC-II Undenatured Type II Collagen

Is UC-II the same as collagen peptides?

No. UC-II is undenatured type II collagen studied in milligrams; peptides are hydrolyzed and commonly studied in grams.

Does 40 mg mean 40 mg of active type II collagen?

Check the exact product specification; total proprietary ingredient mass and active collagen content may differ.

Does it regrow cartilage?

The selected trials measured symptoms and movement, not cartilage regrowth.

Can it replace osteoarthritis care?

No. It does not replace diagnosis, exercise, weight management or indicated medicines.

Does chicken allergy matter?

Yes. Review the finished chicken-derived product with an allergy professional.

What should I track?

Product identity, source, lot, 40 mg schedule if used, pain, stiffness, function and review date.

Glossary

Terms for reading the evidence.

Formulation
The chemical form, source and finished delivery system used in a study.
Daily total
The sum across administrations; it does not reveal amount each time.
WOMAC
A questionnaire for osteoarthritis pain, stiffness and physical function.
DXA
Dual-energy X-ray absorptiometry; some materials can alter the reading itself.
Subgroup
A subset analysis that usually carries more uncertainty than the primary result.
Clinical outcome
A change in symptoms, function or events rather than only a laboratory marker.

How this guide was researched

Accessible official sources and human reports were read on October 9, 2026. Titles, authors, journals, DOI, PMID and visible corrections were checked. An unreported frequency was not guessed.

How this guide was made

Research and drafting were AI-assisted. This draft awaits Doserly editorial review and independent clinical review. See the editorial policy.

Explore the sources

Sources preserve form, amount, frequency, population, duration and outcome.

Showing 6 sources

  1. 01

    Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. ↗

    Multicentre randomized trial

    Current page or report reviewed; scope and limits retained.

    Detail: 191 participants; 40 mg once daily for 180 days; WOMAC outcomes.

  2. 02

    Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. ↗

    Randomized active-comparator trial

    Current page or report reviewed; scope and limits retained.

    Detail: UC-II 40 mg/day in knee osteoarthritis; product-specific study.

  3. 03

    Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers. ↗

    Small randomized activity trial

    Current page or report reviewed; scope and limits retained.

    Detail: 55 participants; 40 mg/day for 120 days; movement and discomfort outcomes.

  4. 04

    UC-II Undenatured Type II Collagen for Knee Joint Flexibility: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study. ↗

    Randomized multicentre trial

    Current page or report reviewed; scope and limits retained.

    Detail: 24-week activity-related joint-discomfort study.

  5. 05

    Questions and Answers on Dietary Supplements ↗

    U.S. regulatory overview

    Current page or report reviewed; scope and limits retained.

    Detail: Supplements generally lack efficacy preapproval.

  6. 06

    Product Licensing ↗

    Canadian licensing overview

    Current page or report reviewed; scope and limits retained.

    Detail: Finished natural health products require licensing and authorized labels.